ANAliya Noor

Aliya Noor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aliya Noor has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular mortality trends in the United States, 1999–2024: an interrupted time-series analysis

    by Ravi Kumar Pandey, Aliya Noor, Muhammad Ahmad, Iqra Moatter Nurie, Ali Rohan, Mazhar Ali, Andrew M. Goldsweig, Martha Gulati, Gregg C. Fonarow

  • Open Access

    Placebo‐Referenced Class‐Level Treatment Effects on Chronic Kidney Disease Progression in Patients With Diabetes: A Network Meta‐Analysis

    by Ravi Kumar Pandey, Maryam Imran, Ishba Manal, Muhammad Ahmad, Aliya Noor, Ali Rohan

    Background and Aim: Multiple pharmacologic therapies reduce chronic kidney disease (CKD) progression in patients with diabetes; however, the absence of head‐to‐head trials and heterogeneity across studies limits the interpretation of indirect comparisons. We evaluated class‐level treatment effects within a predominantly placebo‐centred evidence network. Methods: We conducted a systematic review and class‐level frequentist random‐effects network meta‐analysis of randomised controlled trials evaluating major pharmacologic therapy classes for CKD progression in patients with diabetes. The primary outcome was CKD progression, defined according to the principal composite kidney endpoint reported in each trial. Exploratory analyses evaluated albuminuria reduction and trial‐level surrogate associations between albuminuria and clinical kidney outcomes. Results: Nine trials involving 37,749 participants were included. The evidence network was star‐shaped with placebo as the central comparator. All therapeutic classes were associated with reduced CKD progression compared with placebo. Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) demonstrated the most precise estimate (HR 0.66, 95% CI 0.60–0.74) and were supported by high‐confidence evidence. Confidence in placebo‐referenced estimates for other therapeutic classes ranged from moderate to low because of indirectness, limited trial numbers and differences in study design and patient populations. Findings were generally consistent across sensitivity analyses. No significant association was observed between treatment‐induced albuminuria reduction and clinical kidney outcomes ( R 2 = 0.007), although interpretation was limited by ecological bias and the small number of included studies. Conclusions: Multiple pharmacologic classes were associated with reduced CKD progression compared with placebo in patients with diabetes. Among placebo‐referenced comparisons, the most consistent and highest‐confidence estimates were observed for SGLT2i. However, the predominantly placebo‐centred network, absence of direct active‐comparator trials and important transitivity concerns limit inference regarding comparative efficacy among therapies. Findings should therefore be interpreted as placebo‐referenced class‐level treatment effects rather than evidence of comparative superiority. Direct comparative effectiveness and combination‐therapy trials are needed to define optimal treatment strategies.


  • National trends and disparities in mortality among U.S. older adults, with coexisting Alzheimer's disease and hypertension, 1999-2023

    by Muhammad Ibrahim Rashid, Muhammad Abbas, Ramesha Tahir, Taha Alam, Aliya Noor, Zaigham Ishrat, Muhammad Mudasir, Muhammad Ahsan Sarfraz, Umair Mehboob, Iman Osman Abufatima

    Background: Hypertension (HTN) is a major modifiable risk factor associated with cognitive decline including Alzheimer's disease (AD), which continues to be the leading cause of dementia and death in the United States (U.S.). However, the national mortality burden of coexisting AD and HTN across demographic and geographic groups remains poorly defined. Objective: We aimed to study these trends to provide insights for better prevention, management, and policy planning. Methods: A retrospective analysis was conducted using the CDC WONDER Multiple Cause-of-Death database (1999–2023), focusing on adults aged ≥65 years with AD and HTN. Temporal trends were assessed using Joinpoint regression to estimate annual percent changes. Mortality patterns were examined by sex, race, region, urban-rural status, state, and place of death. Results: Between 1999 and 2023, 504,360 deaths among U.S. adults aged ≥65 years listed both AD and HTN on death certificates, with age-adjusted mortality rates rising from 14.5 to 60.0 per 100,000. Women consistently experienced higher mortality than men (67.5 versus 48.1 per 100,000 in 2023). Non-Hispanic African American adults had the greatest overall burden (57.1) among races. Geographically, mortality was highest in non-metropolitan areas (48.7) and the West region (52.6), More than half of all deaths occurred in nursing homes or long-term care facilities. Conclusions: Mortality for coexisting AD and HTN has quadrupled in the U.S. over the past two decades with substantial variations across groups, highlighting the substantial burden of deaths where AD and HTN coexist and the importance of effective HTN control and dementia care across the lifespan.

  • Open Access

    Normalisation of menstrual pain: the silent driver of gynaecological diagnostic delays among young girls

    by Aliya Noor, Iqra Moatter Nurie

    The pervasive normalisation of dysmenorrhea is a critical public health issue that masks serious gynaecological pathology and leads to significant diagnostic delays. Globally, menstrual pain is frequently dismissed as an inevitable part of womanhood. This normalisation contributes to a diagnostic delay of several years for conditions like endometriosis.1 In Pakistan, socio-cultural taboos exacerbate this problem. Menstruation is shrouded in secrecy and shame, discouraging open discussion and limiting girls' knowledge about their own physiology.2 Studies indicate that the majority of young women manage dysmenorrhea with self-prescribed analgesics or home remedies, with only a small minority seeking professional care.3 When help is sought, symptoms are often minimised by primary healthcare providers, reinforcing a cycle of silence and neglect.4 This collective dismissal has serious consequences. Treating severe pelvic pain as "normal" allows underlying conditions such as endometriosis, adenomyosis, or pelvic inflammatory disease to progress unchecked, potentially affecting future fertility and quality of life.We urge a multi-pronged strategy to address this issue: Integrate comprehensive menstrual health education into national school curricula to foster informed dialogue from a young age. Implement targeted training for primary care providers to improve the recognition of "red flag" symptoms associated with menstrual pain, moving beyond dismissal to proactive investigation. Launch public health campaigns to destigmatise menstruation and encourage timely healthcare-seeking behaviour.Shifting the perception of dysmenorrhea from a normal inconvenience to a potential indicator of pathology is essential. Proactive education, clinical vigilance, and cultural change are imperative to protect the long-term reproductive health of young women in Pakistan.

  • Open Access

    Fasting as a metabolic strategy for cancer prevention: emerging evidence and future direction

    by Aliya Noor, Zahra Batool, Areeba Shaheen, Aiman Shahzad, Ali Rohan, Kamil Ahmad Kamil

  • Open Access

    A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib

    by Mahnoor Jan, Khola Qazi, Aliya Noor, Mawra Naveed, Maliha Khalid, Aminath Waafira

    On 30 September 2025, the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib) as the first targeted oral therapy for chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1-antihistamine treatment. This approval marks a major advancement in CSU management, offering a convenient, precision-based alternative to injectable biologics such as omalizumab. CSU is a chronic, relapsing inflammatory skin disorder characterized by recurrent wheals and angioedema, often accompanied by sleep disturbance, emotional distress, and reduced quality of life. The pathophysiology involves abnormal activation of mast cells and basophils through the IgE receptor (FcεRI) and downstream Bruton’s tyrosine kinase (BTK) signaling, leading to histamine and cytokine release. Remibrutinib, a potent and selective covalent BTK inhibitor, interrupts this inflammatory cascade at its source, thereby providing upstream control of disease activity. FDA approval was based on Phase III REMIX-1 and REMIX-2 trials, which demonstrated rapid, significant, and sustained improvements in Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), and Hives Severity Score (HSS7) compared with placebo. Approximately one-third of patients achieved complete symptom resolution by week 12, and the drug showed an acceptable safety profile with mostly mild adverse events and no need for routine laboratory monitoring. The introduction of remibrutinib represents a paradigm shift in CSU therapy, transitioning from symptomatic relief toward immune-targeted, patient-friendly oral treatment. Future studies should evaluate long-term safety, real-world efficacy, and cost-effectiveness to fully define its role in personalized CSU management.